Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Cancer Genet. 2017 Sep 14;218-219:39–50. doi: 10.1016/j.cancergen.2017.08.006

Table 2.

Patient characteristics

Disease Colon adenocarcinoma Pancreatic adenocarcinoma
Patient # 1 (1A0383) 2 (1A0390) 3 (1A0690) 4 (1A0816) 5 (1A1118) 6 (1A0431) 7 (1A0522) 8 (1A0551) 9 (1A0843) 10 (1A1128)
Pathological stage 3c T3N2M0 4a T3N1M1 3b T3N2(4/17)M0 2 pT4pN0M0 4a TxNxM1a 2b pT3N1M0 2b pT3pN2 2b pT3N1M0 2a pT3N0M0 2b T3N1M0
Age [years] 67 62 50 66 51 54 69 66 45 57
Gender Male Female Female Male Male Male Female Male Female Female
Surgery Hemicolectomy Colon tumor resection Colon resection Right colectomy Hemicolectomy Total pancreatectomy, splenectomy Whipple Whippl Distal pancreatectomy, splenectomy Distal pancreatectomy, splenectomy
Histology tumor scroll 50% tumor, 50% fibrosis 70% tumor, 30% fibrosis 90% tumor, 10% fibrosis 70% tumor, 30% necrosis 90% tumor, 10% fibrosis 30% tumor, 70% fibrosis 40% tumor, 60% fibrosis 50% tumor, 50% fibrosis 50% tumor, 50% fibrosis 40% tumor, 60% fibrosis
Time to metastasis after surgery [months] 70 20 12 5 1 16 9 18 15 7
Metastatic site Mesentery, Anastomosis Liver, Lung Peritoneum, Liver Liver Peritoneum, Liver Peritoneum, Live Live Lung Ovary Liver
Adjuvant therapy before 2nd plasma sample

  1. FOLFOX

  2. FOLFIRI + GI4000 + Bevacizumab

  1. FOLFOX

  1. Capecitabine + Oxaliplatin

  2. Capecitabine + Oxaliplatin + Bevacizumab

  3. Capecitabine +Bevacizumab

  4. 5-FU + Bevacizumab

  5. 5-FU

 / /

  1. Capecitabine + Radiotherapy

  2. Gemcitabine

  1. Veliparib+ FOLFOX

  2. Gemcitabine

  3. MEDI-565

  1. Gemcitabine

  2. Capecitabine

  1. FOLFOX

  2. Capecitabine

  3. PF05082566

  1. Gemcitabine

  2. Capecitabine

FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin); FOLFIRI (Folinic acid, Fluorouracil and Irinotecan); GI4000 (vaccine against mutated Ras); Bevacizumab (anti-VEGF-A antibody); 5-FU (Fluorouracil); Veliparib (poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor); MEDI-565 (anti-CEA/CD3 antibody; PF05082566 (anti-CD137 stimulating antibody).